Publications dans lesquelles il/elle collabore avec Alejandro Escudero Contreras (24)

2024

  1. Interferon and B-cell Signatures Inform Precision Medicine in Lupus Nephritis

    Kidney International Reports, Vol. 9, Núm. 6, pp. 1817-1835

2023

  1. High-content multimodal analysis supports the IL-7/IL-7 receptor axis as a relevant therapeutic target in primary Sjögren's syndrome

    Journal of Autoimmunity

2022

  1. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

    npj Genomic Medicine, Vol. 7, Núm. 1

  2. Effectiveness and safety of tocilizumab in monotherapy in biologic-naïve and non-naïve patients with rheumatoid arthritis in a real-world setting

    Reumatologia Clinica, Vol. 18, Núm. 10, pp. 567-573

2021

  1. A Proinflammatory Cytokine Network Profile in Th1/Type 1 Effector B Cells Delineates a Common Group of Patients in Four Systemic Autoimmune Diseases

    Arthritis and Rheumatology, Vol. 73, Núm. 8, pp. 1550-1561

  2. A new molecular classification to drive precision treatment strategies in primary Sjögren’s syndrome

    Nature Communications, Vol. 12, Núm. 1

  3. Genetic polymorphisms of ggh and abcc2 are associated with methotrexate intolerance in patients with rheumatoid arthritis

    Journal of Clinical Medicine, Vol. 10, Núm. 18

  4. Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases

    Arthritis and Rheumatology, Vol. 73, Núm. 6, pp. 1073-1085

  5. Integrative epigenomics in Sjögren´s syndrome reveals novel pathways and a strong interaction between the HLA, autoantibodies and the interferon signature

    Scientific Reports, Vol. 11, Núm. 1

  6. Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts

    Frontiers in Immunology, Vol. 12

2020

  1. IgM antibodies against malondialdehyde and phosphorylcholine in different systemic rheumatic diseases

    Scientific Reports, Vol. 10, Núm. 1

  2. NFKB2 polymorphisms associate with the risk of developing rheumatoid arthritis and response to TNF inhibitors: Results from the REPAIR consortium

    Scientific Reports, Vol. 10, Núm. 1

  3. Standardization procedure for flow cytometry data harmonization in prospective multicenter studies

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Correction: Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients (The Pharmacogenomics Journal, (2019), 19, 1, (83-96), 10.1038/s41397-018-0057-x)

    Pharmacogenomics Journal

  2. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 12, pp. 899-911

  3. Polymorphisms at phase I-metabolizing enzyme and hormone receptor loci influence the response to anti-TNF therapy in rheumatoid arthritis patients

    Pharmacogenomics Journal, Vol. 19, Núm. 1, pp. 83-96

  4. Reducing or Maintaining the Dose of Subcutaneous Tocilizumab in Patients With Rheumatoid Arthritis in Clinical Remission: A Randomized, Open-Label Trial

    Arthritis and Rheumatology, Vol. 71, Núm. 10, pp. 1616-1625

  5. Steroid hormone-related polymorphisms associate with the development of bone erosions in rheumatoid arthritis and help to predict disease progression: Results from the REPAIR consortium

    Scientific Reports, Vol. 9, Núm. 1

2015

  1. Genetic variants within immune-modulating genes influence the risk of developing rheumatoid arthritis and anti-TNF drug response: A two-stage case-control study

    Pharmacogenetics and Genomics, Vol. 25, Núm. 9, pp. 432-443

  2. Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: A multicenter study

    Pharmacogenetics and Genomics, Vol. 25, Núm. 7, pp. 323-333